There is a new Zantac-NDMA mechanism of action theory which suggests that when ranitidine is exposed to heat it produces unsafe levels of NDMA (nitrosamine impurity called N-nitrosodimethylamine), a probable human carcinogen. Ranitidine is the active ingredient in Zantac.
From this January 2, 2020, Bloomberg news report about this Zantac-NDMA mechanism of action, “Carcinogen in Heartburn Drug May Build in Storage, Lab Finds”, we are presented with this possible scenario:
The heartburn medicine Zantac appears to produce unacceptably high levels of a cancer-causing chemical when exposed to heat for as little as five days, according to a testing laboratory….
New testing by an Alameda, California-based independent laboratory called Emery Pharma found that a combination of heat and time can raise levels of NDMA, potentially while drugs are sitting in packaging well after being analyzed by their manufacturers….
“The more you heat it, the more NDMA you generate,” Emery CEO Ron Najafi said in a telephone interview. “I am worried that if it just sits at home at room temperature, it could gradually generate NDMA.”
Our law firm is currently investigating possible Zantac cancer lawsuits for personal injury and wrongful death cases.[Read article in full at original source]